Danone (DN) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
28 Oct, 2025Executive summary
Q3 2025 like-for-like sales grew 4.8%, driven by a +3.2% volume/mix and +1.6% price, with broad-based growth across all regions and categories, especially strong in China, North Asia & Oceania.
Reported sales reached €6,876m, up 0.7% year-over-year, despite significant currency headwinds (-5.1%).
Specialized nutrition and high-protein dairy platforms were key growth drivers, with strong innovation and market share gains.
Europe showed eight consecutive quarters of positive volume/mix, while CNAO delivered double-digit growth.
North America saw softer growth (+1.5% LFL), constrained by production capacity, but supported by new product launches and the Kate Farms acquisition.
Financial highlights
Like-for-like sales growth of +4.8% year-over-year; reported net sales up +0.7% to €6,876m, with a positive scope effect (+0.7%) from the Kate Farms acquisition and a negative forex impact (-5.1%).
9M 2025 LFL sales growth: +4.4%, totaling €20,578m.
Category LFL growth in Q3: EDP +3.5%, Specialized Nutrition +8.3%, Waters +2.3%.
Volume/mix and price contributed positively across all categories.
Outlook and guidance
2025 guidance confirmed: like-for-like sales growth expected between +3% and +5%, with recurring operating income projected to grow faster than sales.
Management remains confident in future growth, citing capacity expansions, innovation, and ongoing portfolio transformation.
Latest events from Danone
- 4.5% LFL sales growth, margin up 44bps, and strong cash flow despite currency and recall impacts.DN
Q4 202520 Feb 2026 - Targets 3–5% sales growth, €3bn cash flow, and double-digit ROIC, led by health and protein focus.DN
CME 20243 Feb 2026 - 4.0% LFL sales growth, margin up, cash flow +11%, 2024 guidance confirmed.DN
Q2 20242 Feb 2026 - Q3 2024 like-for-like sales up 4.2%, with all regions and categories contributing to growth.DN
Q3 202419 Jan 2026 - Achieved 4.3% LFL sales growth, margin gains, and record €3.0bn free cash flow in FY 2024.DN
Q4 20247 Jan 2026 - Q1 2025 sales rose 4.3% LFL, led by strong growth in China and confirmed 2025 guidance.DN
Q1 202521 Dec 2025 - 4.2% LFL sales growth, margin up 49 bps, and strategic acquisitions highlight H1 2025.DN
Q2 20254 Nov 2025 - Agile structure, innovation, and targeted M&A drive growth in high protein and medical nutrition.DN
Barclays 18th Annual Global Consumer Staples Conference 202520 Oct 2025